Algernon Logo 1.png
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
05 juin 2023 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Logo transparent PNG.png
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
05 juin 2023 06h00 HE | PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
Company logo.png
Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
31 mai 2023 09h19 HE | Pharmazz, Inc.
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
Anthos Logo Transparent.png
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
09 mai 2023 09h45 HE | Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
Anthos Logo Transparent.png
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
05 mai 2023 08h00 HE | Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
04 avr. 2023 10h43 HE | Tiziana Life Sciences Ltd.
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
04 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of...
NovaSignal Logo.png
NovaSignal Donates NovaGuide™ 2 Intelligent Ultrasound to The Jacobs Institute to Advance Stroke Research
28 févr. 2023 09h03 HE | NovaSignal Corporation
LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced the donation of...
formable™ Establishes Platform of World-Renowned Coaches Offering Swim and Run Form Analyses to Maximize Performance and Reduce Injury Among Athletes
18 janv. 2023 09h00 HE | formable
GLEN ROCK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Endurance sports company, AgeGrouper, launches formable™, a dedicated platform that connects athletes with coaches to provide virtual run and swim...
Anthos Logo Transparent.png
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03 janv. 2023 08h00 HE | Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...